$TRUMP
$XAU Capricor shares plunge 80% after FDA rejects its treatment over trial violations
Capricor Therapeutics (NASDAQ: CAPR) shares plunged more than 80% in after-hours trading on Friday after U.S. regulators rejected its muscular dystrophy treatment for the second time, citing serious violations related to the integrity of clinical trial data.

The U.S. Food and Drug Administration said the evidence supporting deramiocel, an experimental treatment for Duchenne muscular dystrophy (DMD), did not meet regulatory approval standards.

#CanBTCReboundAfterFallingBelow60K?